Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared on X:
“Promising practice-changing data from Tata Memorial Hospital
India at ESMO2026!
Phase III trial (n=475) in technically unresectable oral cancer: Weekly paclitaxel-carboplatin + oral metronomic therapy (PCm) vs DCF
- Higher response rates
- Greater conversion to resectability
- Significantly less toxicity
- Non-inferior overall survival
- Outpatient-friendly, without central line
2-year OS: 38.9% vs 29.4%, favouring PCm.
An innovative, pragmatic, potentially more accessible and cost effective regimen from India!
Congratulations Vanita Noronha and the entire team from Tata Memorial Hospital”
You may also be interested in:
Inside ESMO 2026 with Amol Akhade
